COMPAGNIE CHARGEURS INVEST (CRI.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:CRI • FR0000130692

10.14 EUR
-0.02 (-0.2%)
Last: Feb 6, 2026, 07:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CRI. CRI was compared to 15 industry peers in the Industrial Conglomerates industry. Both the profitability and financial health of CRI have multiple concerns. CRI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year CRI was profitable.
  • In the past year CRI had a positive cash flow from operations.
  • Of the past 5 years CRI 4 years were profitable.
  • The reported operating cash flow has been mixed in the past 5 years: CRI reported negative operating cash flow in multiple years.
CRI.PA Yearly Net Income VS EBIT VS OCF VS FCFCRI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

1.2 Ratios

  • With a Return On Assets value of 0.28%, CRI is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • CRI has a worse Return On Equity (1.03%) than 66.67% of its industry peers.
  • The Return On Invested Capital of CRI (5.14%) is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for CRI is below the industry average of 6.70%.
  • The 3 year average ROIC (4.65%) for CRI is below the current ROIC(5.14%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.28%
ROE 1.03%
ROIC 5.14%
ROA(3y)1.05%
ROA(5y)2.21%
ROE(3y)3.33%
ROE(5y)7.74%
ROIC(3y)4.65%
ROIC(5y)5.48%
CRI.PA Yearly ROA, ROE, ROICCRI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15

1.3 Margins

  • CRI has a worse Profit Margin (0.37%) than 66.67% of its industry peers.
  • In the last couple of years the Profit Margin of CRI has declined.
  • CRI has a Operating Margin of 6.41%. This is comparable to the rest of the industry: CRI outperforms 46.67% of its industry peers.
  • CRI's Operating Margin has been stable in the last couple of years.
  • CRI's Gross Margin of 28.51% is on the low side compared to the rest of the industry. CRI is outperformed by 80.00% of its industry peers.
  • CRI's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.41%
PM (TTM) 0.37%
GM 28.51%
OM growth 3Y1.32%
OM growth 5Y1.18%
PM growth 3Y-37.78%
PM growth 5Y-16.13%
GM growth 3Y3.87%
GM growth 5Y1.23%
CRI.PA Yearly Profit, Operating, Gross MarginsCRI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20 25

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRI is destroying value.
  • Compared to 1 year ago, CRI has more shares outstanding
  • CRI has more shares outstanding than it did 5 years ago.
  • CRI has a better debt/assets ratio than last year.
CRI.PA Yearly Shares OutstandingCRI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CRI.PA Yearly Total Debt VS Total AssetsCRI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • CRI has an Altman-Z score of 1.24. This is a bad value and indicates that CRI is not financially healthy and even has some risk of bankruptcy.
  • CRI has a Altman-Z score of 1.24. This is in the lower half of the industry: CRI underperforms 73.33% of its industry peers.
  • CRI has a debt to FCF ratio of 124.09. This is a negative value and a sign of low solvency as CRI would need 124.09 years to pay back of all of its debts.
  • CRI has a worse Debt to FCF ratio (124.09) than 73.33% of its industry peers.
  • A Debt/Equity ratio of 1.38 is on the high side and indicates that CRI has dependencies on debt financing.
  • The Debt to Equity ratio of CRI (1.38) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 124.09
Altman-Z 1.24
ROIC/WACC0.77
WACC6.71%
CRI.PA Yearly LT Debt VS Equity VS FCFCRI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • CRI has a Current Ratio of 1.30. This is a normal value and indicates that CRI is financially healthy and should not expect problems in meeting its short term obligations.
  • CRI has a Current ratio of 1.30. This is amonst the worse of the industry: CRI underperforms 93.33% of its industry peers.
  • A Quick Ratio of 0.86 indicates that CRI may have some problems paying its short term obligations.
  • CRI has a worse Quick ratio (0.86) than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.86
CRI.PA Yearly Current Assets VS Current LiabilitesCRI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

5

3. Growth

3.1 Past

  • CRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 150.24%, which is quite impressive.
  • The earnings per share for CRI have been decreasing by -14.59% on average. This is quite bad
  • CRI shows a small growth in Revenue. In the last year, the Revenue has grown by 6.67%.
  • Measured over the past years, CRI shows a small growth in Revenue. The Revenue has been growing by 3.10% on average per year.
EPS 1Y (TTM)150.24%
EPS 3Y-38.62%
EPS 5Y-14.59%
EPS Q2Q%-146%
Revenue 1Y (TTM)6.67%
Revenue growth 3Y-0.32%
Revenue growth 5Y3.1%
Sales Q2Q%-0.56%

3.2 Future

  • CRI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.19% yearly.
  • The Revenue is expected to grow by 3.45% on average over the next years.
EPS Next Y-39.39%
EPS Next 2Y31.4%
EPS Next 3Y32.19%
EPS Next 5YN/A
Revenue Next Year2.38%
Revenue Next 2Y4.5%
Revenue Next 3Y3.45%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CRI.PA Yearly Revenue VS EstimatesCRI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
CRI.PA Yearly EPS VS EstimatesCRI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5

3

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 78.00 indicates a quite expensive valuation of CRI.
  • CRI's Price/Earnings ratio is a bit more expensive when compared to the industry. CRI is more expensive than 66.67% of the companies in the same industry.
  • CRI's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.93.
  • The Price/Forward Earnings ratio is 13.30, which indicates a correct valuation of CRI.
  • 73.33% of the companies in the same industry are more expensive than CRI, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.77, CRI is valued rather cheaply.
Industry RankSector Rank
PE 78
Fwd PE 13.3
CRI.PA Price Earnings VS Forward Price EarningsCRI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CRI is valued a bit cheaper than the industry average as 73.33% of the companies are valued more expensively.
  • 66.67% of the companies in the same industry are cheaper than CRI, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 74.23
EV/EBITDA 7.32
CRI.PA Per share dataCRI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CRI's earnings are expected to grow with 32.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.4%
EPS Next 3Y32.19%

1

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.28%, CRI has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 2.97, CRI is paying slightly less dividend.
  • CRI's Dividend Yield is slightly below the S&P500 average, which is at 1.81.
Industry RankSector Rank
Dividend Yield 1.28%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
CRI.PA Yearly Dividends per shareCRI.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2025 0.5 1 1.5

5.3 Sustainability

  • CRI pays out 118.52% of its income as dividend. This is not a sustainable payout ratio.
DP118.52%
EPS Next 2Y31.4%
EPS Next 3Y32.19%
CRI.PA Yearly Income VS Free CF VS DividendCRI.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M
CRI.PA Dividend Payout.CRI.PA Dividend Payout, showing the Payout Ratio.CRI.PA Dividend Payout.PayoutRetained Earnings

COMPAGNIE CHARGEURS INVEST

EPA:CRI (2/6/2026, 7:00:00 PM)

10.14

-0.02 (-0.2%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryIndustrial Conglomerates
Earnings (Last)11-05
Earnings (Next)02-11
Inst Owners4.68%
Inst Owner ChangeN/A
Ins Owners64.2%
Ins Owner ChangeN/A
Market Cap252.38M
Revenue(TTM)727.50M
Net Income(TTM)2.70M
Analysts74.29
Price Target12.24 (20.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.28%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP118.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.88%
PT rev (3m)-6.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-43.78%
EPS NY rev (3m)-58.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
Industry RankSector Rank
PE 78
Fwd PE 13.3
P/S 0.35
P/FCF 74.23
P/OCF 10.6
P/B 0.97
P/tB N/A
EV/EBITDA 7.32
EPS(TTM)0.13
EY1.28%
EPS(NY)0.76
Fwd EY7.52%
FCF(TTM)0.14
FCFY1.35%
OCF(TTM)0.96
OCFY9.43%
SpS29.23
BVpS10.49
TBVpS-1.46
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.54
Profitability
Industry RankSector Rank
ROA 0.28%
ROE 1.03%
ROCE 7.02%
ROIC 5.14%
ROICexc 6.13%
ROICexgc 13.12%
OM 6.41%
PM (TTM) 0.37%
GM 28.51%
FCFM 0.47%
ROA(3y)1.05%
ROA(5y)2.21%
ROE(3y)3.33%
ROE(5y)7.74%
ROIC(3y)4.65%
ROIC(5y)5.48%
ROICexc(3y)5.7%
ROICexc(5y)7.48%
ROICexgc(3y)13.2%
ROICexgc(5y)17.03%
ROCE(3y)6.37%
ROCE(5y)7.53%
ROICexgc growth 3Y-6.3%
ROICexgc growth 5Y2.48%
ROICexc growth 3Y-7.54%
ROICexc growth 5Y-2.79%
OM growth 3Y1.32%
OM growth 5Y1.18%
PM growth 3Y-37.78%
PM growth 5Y-16.13%
GM growth 3Y3.87%
GM growth 5Y1.23%
F-Score7
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 124.09
Debt/EBITDA 4.67
Cap/Depr 66.89%
Cap/Sales 2.8%
Interest Coverage 250
Cash Conversion 30.87%
Profit Quality 125.93%
Current Ratio 1.3
Quick Ratio 0.86
Altman-Z 1.24
F-Score7
WACC6.71%
ROIC/WACC0.77
Cap/Depr(3y)59.11%
Cap/Depr(5y)54.94%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)150.24%
EPS 3Y-38.62%
EPS 5Y-14.59%
EPS Q2Q%-146%
EPS Next Y-39.39%
EPS Next 2Y31.4%
EPS Next 3Y32.19%
EPS Next 5YN/A
Revenue 1Y (TTM)6.67%
Revenue growth 3Y-0.32%
Revenue growth 5Y3.1%
Sales Q2Q%-0.56%
Revenue Next Year2.38%
Revenue Next 2Y4.5%
Revenue Next 3Y3.45%
Revenue Next 5YN/A
EBIT growth 1Y57.43%
EBIT growth 3Y1%
EBIT growth 5Y4.32%
EBIT Next Year104.23%
EBIT Next 3Y38.23%
EBIT Next 5YN/A
FCF growth 1Y109.66%
FCF growth 3Y-17.92%
FCF growth 5Y170%
OCF growth 1Y244.24%
OCF growth 3Y-11.82%
OCF growth 5Y11.78%

COMPAGNIE CHARGEURS INVEST / CRI.PA FAQ

What is the ChartMill fundamental rating of COMPAGNIE CHARGEURS INVEST (CRI.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRI.PA.


What is the valuation status of COMPAGNIE CHARGEURS INVEST (CRI.PA) stock?

ChartMill assigns a valuation rating of 3 / 10 to COMPAGNIE CHARGEURS INVEST (CRI.PA). This can be considered as Overvalued.


What is the profitability of CRI stock?

COMPAGNIE CHARGEURS INVEST (CRI.PA) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for CRI stock?

The Price/Earnings (PE) ratio for COMPAGNIE CHARGEURS INVEST (CRI.PA) is 78 and the Price/Book (PB) ratio is 0.97.


How financially healthy is COMPAGNIE CHARGEURS INVEST?

The financial health rating of COMPAGNIE CHARGEURS INVEST (CRI.PA) is 1 / 10.